drugset / Trial / NCT07162649
Dexmedetomidine Nasal Spray for the Treatment of Panic Attacks in Adults
Withdrawn
Tongji University
Shanghai 10th People's Hospital · collabShanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Panic attacks affect 13.2% of adults globally, with acute treatments (e.g., benzodiazepines) carrying dependency risks. Dexmedetomidine, an α₂-adrenergic agonist, achieves peak plasma levels in 5-15 min via nasal delivery and may offer rapid, non-invasive relief for acute panic attacks. Despite preclinical evidence of anxiolytic effects, no randomized trials have evaluated its efficacy for panic attacks.
Timeline
- Start
- 2025-09-01
- Primary completion
- 2027-08-30
- Completion
- 2028-08-30
Outcome
Outcome not reported
Stopped (Business): “The study was terminated due to a strategic prioritization and realignment of the research and development portfolio by the study team.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 30 ug | Intranasal |
Indications
No indication recorded.